相似文献
1
Challenges for the National Institute for Clinical Excellence.
BMJ. 2004 Jul 24;329(7459):227-9. doi: 10.1136/bmj.329.7459.227.
2
National Institute for Clinical Excellence and its value judgments.
BMJ. 2004 Jul 24;329(7459):224-7. doi: 10.1136/bmj.329.7459.224.
3
NICE and its value judgments: option of safe "understudy" treatments should be available.
BMJ. 2004 Sep 25;329(7468):740; author reply 741. doi: 10.1136/bmj.329.7468.740.
4
NICE and its value judgments: utilitarian values are inadequate.
BMJ. 2004 Sep 25;329(7468):740; author reply 741. doi: 10.1136/bmj.329.7468.740-a.
5
The National Institute for Clinical Excellence (NICE).
Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii92-5. doi: 10.1136/ard.61.suppl_2.ii92.
6
Data briefing. NICE (National Institute for Clinical Excellence).
Health Serv J. 2000 Jun 8;110(5708):32.
7
The HSJ interview: Andrew Dillon. The NICE guy. Interview by Lyn Whitfield.
Health Serv J. 2003 Jun 5;113(5858):20-1.
8
NICE and LICE: lessons from a health district. National Institute for Clinical Excellence. Local institutes of clinical excellence.
J Public Health Med. 2002 Mar;24(1):2-5. doi: 10.1093/pubmed/24.1.2.
9
The National Institute for Clinical Excellence and the RCM.
RCM Midwives J. 2002 Aug;5(8):260-1.
10
Evidence-informed evidence-making.
J Health Serv Res Policy. 2008 Jul;13(3):167-73. doi: 10.1258/jhsrp.2008.008027.
引用本文的文献
1
Societal values in the allocation of healthcare resources: is it all about the health gain?
Patient. 2011;4(4):207-25. doi: 10.2165/11588880-000000000-00000.
2
To fund or not to fund: development of a decision-making framework for the coverage of new health technologies.
Pharmacoeconomics. 2011 Sep;29(9):771-80. doi: 10.2165/11539840-000000000-00000.
3
NICE guidelines on anti-tumor necrosis factor therapy for RA.
Nat Clin Pract Rheumatol. 2009 Jan;5(1):16-7. doi: 10.1038/ncprheum0964. Epub 2008 Dec 2.
4
From rationing to rational: the evolving status of NICE.
J R Soc Med. 2008 Sep;101(9):436-42. doi: 10.1258/jrsm.2008.080167.
5
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.
Pharmacoeconomics. 2008;26(2):91-8. doi: 10.2165/00019053-200826020-00001.
6
The increasingly complex fourth hurdle for pharmaceuticals.
Pharmacoeconomics. 2007;25(9):727-34. doi: 10.2165/00019053-200725090-00002.
7
Economic evaluation and decision making in the UK.
Pharmacoeconomics. 2006;24(11):1133-42. doi: 10.2165/00019053-200624110-00009.
8
Information created to evade reality (ICER): things we should not look to for answers.
Pharmacoeconomics. 2006;24(11):1121-31. doi: 10.2165/00019053-200624110-00008.
9
The generalisability of pharmacoeconomic studies: issues and challenges ahead.
Pharmacoeconomics. 2006;24(10):937-45. doi: 10.2165/00019053-200624100-00001.
10
Seven years of feast, seven years of famine: boom to bust in the NHS?
BMJ. 2006 Apr 15;332(7546):906-8. doi: 10.1136/bmj.332.7546.906.
本文引用的文献
1
National Institute for Clinical Excellence and its value judgments.
BMJ. 2004 Jul 24;329(7459):224-7. doi: 10.1136/bmj.329.7459.224.
2
FDA chief wants other rich countries to share drug development costs.
BMJ. 2003 Oct 11;327(7419):830. doi: 10.1136/bmj.327.7419.830-d.
3
Efficacy, safety, and cost of new anticancer drugs.
BMJ. 2002 Aug 3;325(7358):269-71. doi: 10.1136/bmj.325.7358.269.
4
A fair innings for NICE?
Pharmacoeconomics. 2002;20(6):389-91. doi: 10.2165/00019053-200220060-00003.
5
Regulating the pharmaceutical industry.
BMJ. 1997 Jul 26;315(7102):200-1. doi: 10.1136/bmj.315.7102.200.
6
Intergenerational equity: an exploration of the 'fair innings' argument.
Health Econ. 1997 Mar-Apr;6(2):117-32. doi: 10.1002/(sici)1099-1050(199703)6:2<117::aid-hec256>3.0.co;2-b.
Zotero 插件